glp-1 news 2025 october 16 Medscape | Semaglutide, a second-generation receptor agonist, was associated with significantly reduced body weight and other metabolic factors Rising use of GLP-1 medications

Cholelithiasis occurred in 4% of the semaglutide group, versus no incidence in the placebo group [14]

Even among those who switched between GLP-1s, persistence was only 36%

For many patients, GLP-1s and multi-agonists like Lillys GLP-1/GIP Tirzepatide are godsends

Patients who have undergone gallbladder removal may have concerns about taking Ozempic

Inibidores de alfa-glicosidase Os inibidores das enzimas -glicosidases exercem seus efeitos antidiabticos atravs desacelerao e da reduo da taxa de absoro de glicose mediada pela inibio da degradao de carboidratos complexos no trato gastrointestinal (TGI)

PAN Foundation is the only program here that covers the obesity indication (Zepbound) directly, though funding cycles open and close without notice (panapply.org or 1-866-316-7263)